Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the double-blind, U.K. and Danish Phase II STRONG trial in 289 postmenopausal women, NB S101 met the primary endpoint of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury